JP2010527952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527952A5 JP2010527952A5 JP2010508773A JP2010508773A JP2010527952A5 JP 2010527952 A5 JP2010527952 A5 JP 2010527952A5 JP 2010508773 A JP2010508773 A JP 2010508773A JP 2010508773 A JP2010508773 A JP 2010508773A JP 2010527952 A5 JP2010527952 A5 JP 2010527952A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- pharmaceutical composition
- composition according
- group
- ppar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002253 acid Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 3
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 229940009098 aspartate Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- -1 pamoate Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229960005095 pioglitazone Drugs 0.000 claims 2
- 229960004586 rosiglitazone Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- CZIMFHQXGMXDMO-DGROVODQSA-N (3r)-5-hydroxy-7-methoxy-3-[5-[(2r,5r,7r)-2-methyl-1,6-dioxaspiro[4.5]decan-7-yl]pentyl]-3h-2-benzofuran-1-one Chemical group C([C@H](O1)CCCCC[C@@H]2C=3C=C(O)C=C(C=3C(=O)O2)OC)CC[C@@]21CC[C@@H](C)O2 CZIMFHQXGMXDMO-DGROVODQSA-N 0.000 claims 1
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 claims 1
- 229940089960 chloroacetate Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- 229940095060 magnesium tartrate Drugs 0.000 claims 1
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims 1
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims 1
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229940066528 trichloroacetate Drugs 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07108801 | 2007-05-24 | ||
| PCT/EP2008/055171 WO2008141897A1 (en) | 2007-05-24 | 2008-04-28 | Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010527952A JP2010527952A (ja) | 2010-08-19 |
| JP2010527952A5 true JP2010527952A5 (enExample) | 2011-06-16 |
Family
ID=38668873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508773A Withdrawn JP2010527952A (ja) | 2007-05-24 | 2008-04-28 | Ｐｐａｒ−ガンマアゴニストの使用に起因する有害作用の防止に有用な組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100305204A1 (enExample) |
| EP (1) | EP2162127A1 (enExample) |
| JP (1) | JP2010527952A (enExample) |
| KR (1) | KR20100017460A (enExample) |
| CN (1) | CN101677983B (enExample) |
| AU (1) | AU2008253134A1 (enExample) |
| BR (1) | BRPI0812306A2 (enExample) |
| CA (1) | CA2687154A1 (enExample) |
| MX (1) | MX2009012429A (enExample) |
| WO (1) | WO2008141897A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940884B (zh) * | 2012-11-19 | 2013-11-06 | 上海市肿瘤研究所 | 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用 |
| KR102072075B1 (ko) * | 2018-06-21 | 2020-01-31 | 울산과학기술원 | TRIM25을 유효성분으로 함유하는 PPARγ 분해용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1133010B (it) * | 1980-05-15 | 1986-07-09 | Sigma Tau Ind Farmaceuti | Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo |
| IT1263004B (it) * | 1992-10-08 | 1996-07-23 | Sigma Tau Ind Farmaceuti | Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti. |
| IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
| IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
| DE69942672D1 (de) * | 1998-12-17 | 2010-09-23 | Mindset Biopharmaceuticals Usa | Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns |
| CN1812988A (zh) * | 2003-05-13 | 2006-08-02 | 斯索恩有限公司 | 制备噻唑烷二酮衍生物的方法及其化合物 |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
-
2008
- 2008-04-28 WO PCT/EP2008/055171 patent/WO2008141897A1/en not_active Ceased
- 2008-04-28 BR BRPI0812306-3A2A patent/BRPI0812306A2/pt not_active IP Right Cessation
- 2008-04-28 KR KR1020097024847A patent/KR20100017460A/ko not_active Withdrawn
- 2008-04-28 JP JP2010508773A patent/JP2010527952A/ja not_active Withdrawn
- 2008-04-28 US US12/599,327 patent/US20100305204A1/en not_active Abandoned
- 2008-04-28 CA CA002687154A patent/CA2687154A1/en not_active Abandoned
- 2008-04-28 MX MX2009012429A patent/MX2009012429A/es unknown
- 2008-04-28 CN CN2008800173198A patent/CN101677983B/zh not_active Expired - Fee Related
- 2008-04-28 AU AU2008253134A patent/AU2008253134A1/en not_active Abandoned
- 2008-04-28 EP EP08749795A patent/EP2162127A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541595A5 (enExample) | ||
| JP2011502997A5 (enExample) | ||
| HRP20150592T1 (hr) | Organoborni esterski spojevi i njihove farmaceutske kompozicije | |
| JP2012526140A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2013519632A5 (enExample) | ||
| ES2300141T3 (es) | Asociaciones de riluzol y levodopa para el tratamiento de la enfrmedad de parkinson. | |
| JP5788527B2 (ja) | キナーゼ阻害剤の副作用低減剤 | |
| JP2010506846A (ja) | フェニルアルキルカルバメート組成物 | |
| JP2011506587A5 (enExample) | ||
| EP2550957A1 (en) | Effervescent formulations of vildagliptin | |
| JP2010527952A5 (enExample) | ||
| KR20110027711A (ko) | 로수바스타틴 칼슘의 약학적 조성물 | |
| CN1298314C (zh) | 含有碱性氨基酸ⅱ的o－乙酰水杨酸的稳定盐 | |
| CN102655866A (zh) | 糖尿病的治疗或预防药 | |
| WO2013091704A1 (en) | Pharmaceutical composition comprising fingolimod | |
| JP5786714B2 (ja) | 神経障害性疼痛の治療剤又は予防剤 | |
| US20070259941A1 (en) | Ramipril formulation | |
| JP2005523269A5 (enExample) | ||
| JP5776355B2 (ja) | 内服液剤 | |
| US20080103202A1 (en) | Method of preparing creatine ester salts and uses thereof. | |
| ES2443968T3 (es) | Composiciones farmacéuticas de olmesartán | |
| JP2013526503A (ja) | キサンチンオキシダーゼ阻害剤とアンジオテンシンｉｉ受容体アンタゴニストとの合剤およびその使用 | |
| ES2672986T3 (es) | Composiciones farmacéuticas que contienen dexketoprofeno y tramadol | |
| WO2015198225A1 (en) | Oral pharmaceutical composition of tofacitinib |